Latest news

Daily Snap - 27. August 2025

Daily Snap - 27. August 2025

Joachim Eeckhout
Regeneron's cemdisiran achieves Phase 3 win, confirming siRNA’s potential in treating myasthenia gravis

Regeneron's cemdisiran achieves Phase 3 win, confirming siRNA’s potential in treating myasthenia gravis

Eduardo Longoria
Fosun’s $670 million deal with Sitala keeps pointing towards West’s appetite for Chinese innovation

Fosun’s $670 million deal with Sitala keeps pointing towards West’s appetite for Chinese innovation

Eduardo Longoria
Daily Snap - 25. August 2025

Daily Snap - 25. August 2025

Joachim Eeckhout
AbbVie bets $1.2B on psychedelic breakthrough for depression

AbbVie bets $1.2B on psychedelic breakthrough for depression

Joachim Eeckhout
LB Pharma targets IPO lifeline to fund schizophrenia drug trial

LB Pharma targets IPO lifeline to fund schizophrenia drug trial

Joachim Eeckhout
Daily Snap - 22. August 2025

Daily Snap - 22. August 2025

Joachim Eeckhout
Gilead bets big on in vivo cell therapy with $350M Interius buy

Gilead bets big on in vivo cell therapy with $350M Interius buy

Eduardo Longoria
FDA OKs Ionis' Dawnzera, a new RNA-based drug for rare swelling disorder

FDA OKs Ionis' Dawnzera, a new RNA-based drug for rare swelling disorder

Eduardo Longoria
Daily Snap - 21. August 2025

Daily Snap - 21. August 2025

Joachim Eeckhout
Celldex shares drop 18% after it follows Allakos’ footsteps in eosinophilic esophagitis

Celldex shares drop 18% after it follows Allakos’ footsteps in eosinophilic esophagitis

Eduardo Longoria
Jazz bets $42.5M on Saniona’s next-gen epilepsy drug to avoid Potiga’s pitfalls

Jazz bets $42.5M on Saniona’s next-gen epilepsy drug to avoid Potiga’s pitfalls

Eduardo Longoria
FirstBack
12345678
Next Last